Anti-angiogenic vaccines as a treatment modality for cancer.
Targeting angiogenesis to inhibit tumor development is now considered a valid approach to disease modulation. Recently, a number of laboratories have focused their research on the development of cancer vaccines that target modulators of angiogenesis. In this review we describe a number of novel vaccines that target mediators of angiogenesis and inhibit tumor progression in preclinical models.
Plum
Stacy M
SM
EntreMed Inc, 9640 Medical Center Drive, Rockville, MD 20850, USA. stacyp@entremed.com
Fogler
William E
WE
D020533:Angiogenesis Inhibitors / Q000276:immunology* / Q000627:therapeutic use*; D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control / Q000628:therapy*
D020533:Angiogenesis Inhibitors; D019496:Cancer Vaccines